Electrophysiologic and Hemodynamic Effects of A Single Oral Administration of Pirmenol.
-
- INO Takeshi
- The First Department of Internal Medicine, Nippon Medical School
-
- ATARASHI Hirotsugu
- The First Department of Internal Medicine, Nippon Medical School
-
- SAITOH Hirokazu
- The First Department of Internal Medicine, Nippon Medical School
-
- ONODERA Takeo
- The First Department of Internal Medicine, Nippon Medical School
-
- KUROKI Shin-ichi
- The First Department of Internal Medicine, Nippon Medical School
-
- HIRAYAMA Yoshiyuki
- The First Department of Internal Medicine, Nippon Medical School
-
- KURUMA Akinori
- The First Department of Internal Medicine, Nippon Medical School
-
- YASHIMA Masa-aki
- The First Department of Internal Medicine, Nippon Medical School
-
- OHMURA Kazuko
- The First Department of Internal Medicine, Nippon Medical School
-
- TADERA Takeshi
- The First Department of Internal Medicine, Nippon Medical School
-
- ENDOH Yasumi
- The First Department of Internal Medicine, Nippon Medical School
-
- NOMURA Atsunori
- The First Department of Internal Medicine, Nippon Medical School
-
- KATOH Takao
- The First Department of Internal Medicine, Nippon Medical School
-
- HAYAKAWA Hirokazu
- The First Department of Internal Medicine, Nippon Medical School
Bibliographic Information
- Other Title
-
- Pirmenol単回経口投与の電気生理学的効果と心血行動態に及ぼす影響
Search this article
Abstract
The electrophysiologic and hemodynamic effects and the pharmacokinetics of a single oral administration of pirmenol were evaluated in 20 patients with supraventricular tachycardia (SVT). Pirmenol, at 1hr after administration, significantly shortened sinus cycle length and sinoatrial conduction time. HV interval (46±10msec to 54±11msec, P<0.01), refractory period of the right atrium and the right ventricle were significantly prolonged. Furthermore, anterograde refractory period of accessory pathway and retrograde refractory period of AV node and accessory pathway were prolonged. Hemodynamic study revealed increased systemic and pulmonary vascular resistance and decreased stroke volume index. Induction of SVT was suppressed in 11 out of 16 patients. Among 5 patients who were not suppressed at 1hr, 2 patients resulted in noninducible at 2hr after administration. Plasma concentration of pirmenol at 1hr after administration was 1.0±0.4μg/ml in effective cases and was 0.4±0.5μg/ml in failed cases (P<0.05). Pharmacokinetics of single oral pirmenol were, tmax of 2.9hr, Cmax of 1.4μg/ml, t1/2 of 6.8hr and AUC of 18.7μg·hr/ml. In conclusion, a single oral administration of pirmenol was highly effective in suppression of induction of SVT with sufficient hemodynamic tolerance.
Journal
-
- Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
-
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 22 (4), 745-756, 1991
The Japanese Society of Clinical Pharmacology and Therapeutics
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001205340697856
-
- NII Article ID
- 130002045730
- 80006280113
-
- ISSN
- 18828272
- 03881601
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed